Maruyama, D., Gomez, E. J., Jalaluddin, M., Izeradjene, K., Greenberg, E., Ramathal, C., Ku, M. (2025). A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7093